Nothing Special   »   [go: up one dir, main page]

RS58929B1 - Derivati etinila kao modulatori metabotropnih glutamatnih receptora - Google Patents

Derivati etinila kao modulatori metabotropnih glutamatnih receptora

Info

Publication number
RS58929B1
RS58929B1 RS20190819A RSP20190819A RS58929B1 RS 58929 B1 RS58929 B1 RS 58929B1 RS 20190819 A RS20190819 A RS 20190819A RS P20190819 A RSP20190819 A RS P20190819A RS 58929 B1 RS58929 B1 RS 58929B1
Authority
RS
Serbia
Prior art keywords
receptor modulators
glutamate receptor
metabotropic glutamate
ethynyl derivatives
ethynyl
Prior art date
Application number
RS20190819A
Other languages
English (en)
Inventor
Barbara Biemans
Wolfgang Guba
Georg Jaeschke
Lothar Lindemann
Fionn O`Hara
Antonio Ricci
Daniel Rueher
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS58929B1 publication Critical patent/RS58929B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20190819A 2015-07-15 2016-07-11 Derivati etinila kao modulatori metabotropnih glutamatnih receptora RS58929B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176854 2015-07-15
PCT/EP2016/066393 WO2017009275A1 (en) 2015-07-15 2016-07-11 Ethynyl derivatives as metabotropic glutamate receptor modulators
EP16739442.8A EP3322701B1 (en) 2015-07-15 2016-07-11 Ethynyl derivatives as metabotropic glutamate receptor modulators

Publications (1)

Publication Number Publication Date
RS58929B1 true RS58929B1 (sr) 2019-08-30

Family

ID=53758003

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190819A RS58929B1 (sr) 2015-07-15 2016-07-11 Derivati etinila kao modulatori metabotropnih glutamatnih receptora

Country Status (30)

Country Link
US (3) US10189848B2 (sr)
EP (1) EP3322701B1 (sr)
JP (1) JP6761821B2 (sr)
KR (1) KR20180026438A (sr)
CN (1) CN107580598B (sr)
AR (1) AR105341A1 (sr)
AU (1) AU2016292863B2 (sr)
CA (1) CA2984711C (sr)
CL (1) CL2018000036A1 (sr)
CO (1) CO2017011174A2 (sr)
CR (1) CR20180022A (sr)
DK (1) DK3322701T3 (sr)
ES (1) ES2733468T3 (sr)
HR (1) HRP20191139T1 (sr)
HU (1) HUE045145T2 (sr)
IL (1) IL255096B (sr)
LT (1) LT3322701T (sr)
MA (1) MA42442B1 (sr)
MX (1) MX2018000592A (sr)
PE (1) PE20180356A1 (sr)
PH (1) PH12018500106A1 (sr)
PL (1) PL3322701T3 (sr)
PT (1) PT3322701T (sr)
RS (1) RS58929B1 (sr)
RU (1) RU2721776C9 (sr)
SI (1) SI3322701T1 (sr)
TR (1) TR201909160T4 (sr)
TW (1) TWI612962B (sr)
UA (1) UA120463C2 (sr)
WO (1) WO2017009275A1 (sr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359293B (es) 2012-06-13 2018-09-24 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
RS58929B1 (sr) 2015-07-15 2019-08-30 Hoffmann La Roche Derivati etinila kao modulatori metabotropnih glutamatnih receptora
PL3484889T3 (pl) * 2016-07-18 2020-12-28 F. Hoffmann-La Roche Ag Pochodne etynylu
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
EP3827001A1 (en) 2018-07-26 2021-06-02 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
BRPI0610209A2 (pt) * 2005-05-24 2010-06-01 Serono Lab derivados espiro tricìclicos como moduladores de crth2
JP2010502617A (ja) 2006-08-31 2010-01-28 シェーリング コーポレイション 抗菌物質として有用なヒダントイン誘導体
BRPI0812363A2 (pt) 2007-06-03 2015-02-03 Univ Vanderbilt Moduladores alostéricos positivos de mglurs de benzamida e métodos de preparação e utilização dos mesmos
CA2712605C (en) 2008-02-01 2017-02-07 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Monoclonal antibodies for ebola and marburg viruses
WO2010081492A1 (en) 2009-01-19 2010-07-22 Fondazione Ospedale Maggiore Policlinico Mangiagalli Regina Elena - Milano Melanocortin analogs with antimicrobial activity
WO2011071574A2 (en) 2009-09-02 2011-06-16 United States Deparment Of The Army, As Represented By The Secretary Of The Army Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
CN102740699A (zh) 2009-09-04 2012-10-17 范德比尔特大学 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
ES2580333T3 (es) 2011-04-26 2016-08-23 F. Hoffmann-La Roche Ag Derivados de pirazolidin-3-ona
PL2702051T3 (pl) 2011-04-26 2015-08-31 Hoffmann La Roche Pochodne etynylu jako pozytywne allosteryczne modulatory mglur5
CA2837312A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
RS55313B1 (sr) 2012-07-17 2017-03-31 Hoffmann La Roche Ariletinil derivati
UA114934C2 (uk) 2012-10-18 2017-08-28 Ф. Хоффманн-Ля Рош Аг Похідне етинілу як модулятор активності метаботропного глутаматного рецептора підтипу 5
AU2013331782B2 (en) 2012-10-18 2017-03-09 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mGluR5 receptor activity
CN105121424B (zh) 2013-02-18 2019-01-22 华领医药技术(上海)有限公司 mGluR调节剂
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EP3049409B1 (en) * 2013-09-25 2017-05-03 F. Hoffmann-La Roche AG Ethynyl derivatives
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
US20170065702A1 (en) 2014-02-19 2017-03-09 Cangene Corporation Methods of modulating an immune response
CR20160384A (es) 2014-02-25 2016-11-07 Hoffmann La Roche Derivados de etilino
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
EP3271353B1 (en) 2015-03-19 2019-11-27 H. Hoffnabb-La Roche Ag 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4
RS58929B1 (sr) 2015-07-15 2019-08-30 Hoffmann La Roche Derivati etinila kao modulatori metabotropnih glutamatnih receptora
PL3484889T3 (pl) 2016-07-18 2020-12-28 F. Hoffmann-La Roche Ag Pochodne etynylu

Also Published As

Publication number Publication date
US20180134721A1 (en) 2018-05-17
RU2721776C2 (ru) 2020-05-22
AU2016292863B2 (en) 2020-03-05
DK3322701T3 (da) 2019-07-08
EP3322701A1 (en) 2018-05-23
US20190119290A1 (en) 2019-04-25
PT3322701T (pt) 2019-06-28
RU2018103944A3 (sr) 2019-12-13
UA120463C2 (uk) 2019-12-10
PL3322701T3 (pl) 2019-09-30
MX2018000592A (es) 2018-04-24
BR112017023084A2 (pt) 2018-07-10
TW201707705A (zh) 2017-03-01
CN107580598A (zh) 2018-01-12
PE20180356A1 (es) 2018-02-21
TWI612962B (zh) 2018-02-01
EP3322701B1 (en) 2019-05-01
HUE045145T2 (hu) 2019-12-30
IL255096B (en) 2020-01-30
MA42442A (fr) 2018-05-23
RU2721776C9 (ru) 2020-10-22
US11034699B2 (en) 2021-06-15
CR20180022A (es) 2018-02-26
CO2017011174A2 (es) 2018-01-31
AR105341A1 (es) 2017-09-27
HRP20191139T1 (hr) 2019-09-20
CA2984711C (en) 2023-08-29
AU2016292863A1 (en) 2017-11-02
PH12018500106A1 (en) 2018-07-23
LT3322701T (lt) 2019-07-10
IL255096A0 (en) 2017-12-31
CA2984711A1 (en) 2017-01-19
JP6761821B2 (ja) 2020-09-30
JP2018524305A (ja) 2018-08-30
SI3322701T1 (sl) 2019-08-30
CL2018000036A1 (es) 2018-06-29
CN107580598B (zh) 2020-11-13
US20210269452A1 (en) 2021-09-02
ES2733468T3 (es) 2019-11-29
US10189848B2 (en) 2019-01-29
RU2018103944A (ru) 2019-08-16
KR20180026438A (ko) 2018-03-12
US12006323B2 (en) 2024-06-11
MA42442B1 (fr) 2019-07-31
WO2017009275A1 (en) 2017-01-19
TR201909160T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
IL255096A0 (en) Ethinylestradiol as metabotropic glutamate receptor modulators
HRP20190024T1 (hr) Derivati hidroksialkil-piperazina kao modulatori receptora cxcr3
IL249267A0 (en) Materials containing carbonitrile and their use for selective modulation of the androgen receptor
HRP20182016T1 (hr) Derivati etinila
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
HK1215573A1 (zh) 作為代謝型谷氨酸受體拮抗劑的乙炔基衍生物
HK1246790A1 (zh) 乙炔基衍生物
HK1249096A1 (zh) 乙炔基衍生物